Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis

被引:107
作者
Saouaf, Sandra J. [1 ]
Li, Bin [1 ]
Zhang, Geng [1 ]
Shen, Yuan [1 ]
Furuuchi, Narumi [1 ]
Hancock, Wayne W. [1 ,2 ]
Greene, Mark I. [1 ]
机构
[1] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA
关键词
T cell; Suppression; Autoimmunity; Rheumatoid arthritis; RHEUMATOID-ARTHRITIS; FOXP3; TRICHOSTATIN; EXPRESSION; ACETYLATION; SUPPRESSION; MODULATION; DEPLETION; STRATEGY; THERAPY;
D O I
10.1016/j.yexmp.2009.06.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Collagen-induced arthritis (CIA) is an established mouse model of disease with hallmarks of clinical rheumatoid arthritis. Histone/protein deacetylase inhibitors (HDACi) are known to inhibit the pathogenesis of CIA and other models of autoimmune disease, although the mechanisms responsible are unclear. Regulatory T cell (Treg) function is defective in rheumatoid arthritis. FOXP3 proteins in Tregs are present in a dynamic protein complex containing histone acetyltransferase and HDAC enzymes, and FOXP3 itself is acetylated on lysine residues. We therefore investigated the effects of HDACi therapy on regulatory T cell function in the CIA model. Administration of an HDACi, valproic acid (VPA), significantly decreased disease incidence (p<0.005) and severity (p<0.03) in CIA. In addition, VPA treatment increased both the suppressive function of CD4(+)CD25(+) Tregs (p<0.04) and the numbers of CD25(+)FOXP3(+) Tregs in vivo. Hence, clinically approved HDACi such as VPA may limit autoimmune disease in vivo through effects on the production and function of FOXP3(+) Treg cells. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 32 条
[1]   Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines [J].
Buglio, Daniela ;
Georgakis, Georgios V. ;
Hanabuchi, Shino ;
Arima, Kazuhiko ;
Khaskhely, Noor M. ;
Liu, Yong-Jun ;
Younes, Anas .
BLOOD, 2008, 112 (04) :1424-1433
[2]   Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis [J].
Camelo, S ;
Iglesias, AH ;
Hwang, D ;
Due, B ;
Ryu, H ;
Smith, K ;
Gray, SG ;
Imitola, J ;
Duran, G ;
Assaf, B ;
Langley, B ;
Khoury, SJ ;
Stephanopoulos, G ;
De Girolami, U ;
Ratan, RR ;
Ferrante, RJ ;
Dangond, F .
JOURNAL OF NEUROIMMUNOLOGY, 2005, 164 (1-2) :10-21
[3]   A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis [J].
Chung, YL ;
Lee, MY ;
Wang, AJ ;
Yao, LF .
MOLECULAR THERAPY, 2003, 8 (05) :707-717
[4]   Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy [J].
Ehrenstein, MR ;
Evans, JG ;
Singh, A ;
Moore, S ;
Warnes, G ;
Isenberg, DA ;
Mauri, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (03) :277-285
[5]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992
[6]   The role of regulatory T cells in antigen-induced arthritis:: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells [J].
Frey, O ;
Petrow, PK ;
Gajda, M ;
Siegmund, K ;
Huehn, J ;
Scheffold, A ;
Hamann, A ;
Radbruch, A ;
Bräuer, R .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (02) :R291-R301
[7]   Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition [J].
Garcia, BA ;
Busby, SA ;
Shabanowitz, J ;
Hunt, DF ;
Mishra, N .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (06) :2032-2042
[8]   Antiepileptic drugs - From scientific evidence to clinical practice [J].
Garcia-Morales, Irene ;
Rieger, Jeronimo Sancho ;
Gil-Nagel, Antonio ;
Fernandez, Jose Luis Herranz .
NEUROLOGIST, 2007, 13 (06) :S20-S28
[9]   Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis [J].
Gray, Steven G. ;
Dangond, Fernando .
EPIGENETICS, 2006, 1 (02) :67-75
[10]   Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain [J].
Gu, W ;
Roeder, RG .
CELL, 1997, 90 (04) :595-606